INCY

Business Context and Reporting Period

Company: Incyte Corporation (Incyte)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: Incyte is a drug discovery and development company focused on proprietary small molecule drugs for oncology, inflammation, diabetes, and HIV. The company operates as a single segment and relies on collaborations (notably with Pfizer) and licensing for revenue, while incurring significant research and development (R&D) costs.

Key Financial Metrics

Note: Debt figures represent the sum of Convertible Senior Notes ($124,320) and Convertible Subordinated Notes ($264,577) as of March 31, 2008.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues dropped 82% to $1.3 million from $7.4 million. This was driven primarily by a decrease in contract revenues ($0.6 million vs. $6.1 million) as the company fully recognized revenues associated with the Pfizer upfront fee and related debt discounts. License and royalty revenues also declined to $0.7 million from $1.3 million.
• Increased Losses: Net loss widened to $40.2 million from $22.1 million. This increase was largely due to higher R&D expenses ($33.0 million vs. $23.9 million) driven by increased headcount and clinical pipeline advancement, partially offset by a decrease in interest income.
• Liquidity Improvement: Cash and cash equivalents increased significantly to $162.7 million from $108.9 million at the end of 2007, and $20.3 million in the prior year quarter. This increase was fueled by net cash provided by investing activities ($90.7 million), primarily from the sale and maturity of marketable securities ($89.6 million).
• Expense Growth: R&D expenses rose 38% year-over-year. Selling, general, and administrative (SG&A) expenses increased slightly to $4.4 million from $3.7 million.

Outlook, Risks, and Management Commentary

• Pipeline Status: Incyte has progressed eight internally developed compounds into clinical trials, with four in Phase II. Key programs include JAK inhibitors (INCB18424) for myelofibrosis and rheumatoid arthritis, and CCR5 antagonists for HIV. The company recently announced it would not advance its lead CCR5 antagonist into Phase IIb trials and is seeking to out-license the program.
• Liquidity and Capital Needs: Management believes current cash, cash equivalents, and marketable securities ($219.2 million total) are adequate for at least the next twelve months. However, the company expects to incur additional losses for several years and may need to raise additional capital in the future.
• Debt Obligations: The company carries significant debt, including $151.8 million in 3.875% convertible senior notes due 2011 and $250.0 million in 3.875% convertible subordinated notes due 2011. Annual interest payments are substantial, and the company may need to liquidate securities to meet obligations if operating cash flow remains negative.
• Risk Factors: Key risks include the failure of drug candidates in clinical trials, inability to obtain regulatory approval, dependence on third-party manufacturers and collaborators (specifically Pfizer for CCR2 antagonists), and the need for future capital raises which could be dilutive.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $37.4 million quarterly operating cash burn against the $219.2 million total liquid asset base.
• Debt Maturity: Confirm the repayment or conversion strategy for the $401.8 million in convertible notes maturing in 2011.
• Revenue Concentration: Note that one customer contributed 45% of revenues in Q1 2008 (down from 82% in Q1 2007), indicating a shift away from the Pfizer collaboration revenue stream.
• Clinical Milestones: Monitor the status of the CCR5 out-licensing effort and the delayed psoriasis trial for INCB18424.
• Restructuring Accruals: Review the utilization of the $8.6 million restructuring accrual balance related to lease commitments and workforce reductions.